These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25985292)

  • 1. Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein.
    Ahsan N; Mishra S; Jain MK; Surolia A; Gupta S
    Sci Rep; 2015 May; 5():9862. PubMed ID: 25985292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity.
    Ahsan N; Siddique IA; Gupta S; Surolia A
    Eur J Med Chem; 2018 Jan; 143():1174-1184. PubMed ID: 29150334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity.
    Jha NN; Ghosh D; Das S; Anoop A; Jacob RS; Singh PK; Ayyagari N; Namboothiri IN; Maji SK
    Sci Rep; 2016 Jun; 6():28511. PubMed ID: 27338805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson's disease.
    Gadad BS; Subramanya PK; Pullabhatla S; Shantharam IS; Rao KS
    Curr Pharm Des; 2012; 18(1):76-84. PubMed ID: 22211690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seeking a mechanism for the toxicity of oligomeric α-synuclein.
    Roberts HL; Brown DR
    Biomolecules; 2015 Mar; 5(2):282-305. PubMed ID: 25816357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of Cu
    Lorentzon E; Kumar R; Horvath I; Wittung-Stafshede P
    Biometals; 2020 Jun; 33(2-3):97-106. PubMed ID: 32170541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin inhibits aggregation of alpha-synuclein.
    Pandey N; Strider J; Nolan WC; Yan SX; Galvin JE
    Acta Neuropathol; 2008 Apr; 115(4):479-89. PubMed ID: 18189141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.
    Perni M; Galvagnion C; Maltsev A; Meisl G; Müller MB; Challa PK; Kirkegaard JB; Flagmeier P; Cohen SI; Cascella R; Chen SW; Limbocker R; Sormanni P; Heller GT; Aprile FA; Cremades N; Cecchi C; Chiti F; Nollen EA; Knowles TP; Vendruscolo M; Bax A; Zasloff M; Dobson CM
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):E1009-E1017. PubMed ID: 28096355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism.
    Liu Z; Yu Y; Li X; Ross CA; Smith WW
    Pharmacol Res; 2011 May; 63(5):439-44. PubMed ID: 21237271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative.
    Gautam S; Karmakar S; Batra R; Sharma P; Pradhan P; Singh J; Kundu B; Chowdhury PK
    Biochim Biophys Acta Proteins Proteom; 2017 May; 1865(5):589-603. PubMed ID: 28238838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity.
    Kumar S; Jangir DK; Kumar R; Kumari M; Bhavesh NS; Maiti TK
    ACS Chem Neurosci; 2018 Feb; 9(2):230-240. PubMed ID: 28841377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DEAD-box RNA helicase Dbp4/DDX10 is an enhancer of α-synuclein toxicity and oligomerization.
    Popova B; Wang D; Pätz C; Akkermann D; Lázaro DF; Galka D; Kolog Gulko M; Bohnsack MT; Möbius W; Bohnsack KE; Outeiro TF; Braus GH
    PLoS Genet; 2021 Mar; 17(3):e1009407. PubMed ID: 33657088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
    Zaidi FK; Deep S
    Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution.
    Li X; Dong C; Hoffmann M; Garen CR; Cortez LM; Petersen NO; Woodside MT
    Sci Rep; 2019 Feb; 9(1):1734. PubMed ID: 30741954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
    Collier TJ; Srivastava KR; Justman C; Grammatopoulous T; Hutter-Paier B; Prokesch M; Havas D; Rochet JC; Liu F; Jock K; de Oliveira P; Stirtz GL; Dettmer U; Sortwell CE; Feany MB; Lansbury P; Lapidus L; Paumier KL
    Neurobiol Dis; 2017 Oct; 106():191-204. PubMed ID: 28711409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pathological G51D Mutation in Alpha-Synuclein Oligomers Confers Distinct Structural Attributes and Cellular Toxicity.
    Xu CK; Castellana-Cruz M; Chen SW; Du Z; Meisl G; Levin A; Mannini B; Itzhaki LS; Knowles TPJ; Dobson CM; Cremades N; Kumita JR
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture.
    Rutherford NJ; Giasson BI
    Neurosci Lett; 2015 Jun; 597():43-8. PubMed ID: 25892596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.